Blood

Vol. 146, Issue 3 Issue 3 2025
20
Articles

Articles in this Issue

International consensus statement on diagnosis, evaluation, and research of Richter transformation: the ERIC recommendations

Adam S. Kittai, Monia Marchetti, Othman Al-Sawaf et al. Jul 17, 2025 pp. 291-303 10.1182/blood.2024028064

Abstract Richter transformation (RT) is defined as an aggressive lymphoma emerging in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL). Despite novel thera...

Platelet NLRP6: a hidden talent?

Samithamby Jeyaseelan Jul 17, 2025 pp. 271-273 10.1182/blood.2025029739

Clinical phenotype and pathophysiological mechanisms underlying qualitative low VWF

Ferdows Atiq, Robin Blok, Calvin B. van Kwawegen et al. Jul 17, 2025 pp. 369-381 10.1182/blood.2024028035

Abstract Previous reports have highlighted that some patients with low von Willebrand factor (VWF) with significant bleeding were diagnosed based on an isolated but persistent reduct...

PROTACtion against BCL-xL in post-MPN AML

Nicole S. Arellano, Shannon E. Elf Jul 17, 2025 pp. 266-267 10.1182/blood.2025029273

Secondary blastoid plasma cell leukemia: can an old dog learn new tricks?

Jinjun Cheng, Jiehao Zhou Jul 17, 2025 pp. 396-396 10.1182/blood.2025029282

An unbiased genomewide screen uncovers 7 genes that drive hematopoietic stem cell fate from mouse embryonic stem cells

Luis G. Palma, Gayathri M. Kartha, María Maqueda et al. Jul 17, 2025 pp. 328-340 10.1182/blood.2024027742

Abstract Hematopoietic stem cells (HSCs) possess the ability to long term reconstitute all the blood lineages and generate all blood cell types. As such, the in vitro generation of H...

Duployez N, Largeaud L, Duchmann M, et al. Prognostic impact of <i>DDX41</i> germline mutations in intensively treated acute myeloid leukemia patients: an ALFA-FILO study. <i>Blood</i>. 2022;140(7):756-768.

Jul 17, 2025 pp. 397-397 10.1182/blood.2025029967

m6A meets T-ALL: HNRNPC and FTO as new therapeutic targets

Xueqin Xie, Michael G. Kharas Jul 17, 2025 pp. 261-262 10.1182/blood.2025029382

Type 1 von Willebrand disease: does it need a sibling?

Ravi Sarode Jul 17, 2025 pp. 270-271 10.1182/blood.2025029448

Epigenetic drug remedies for SCD root cause pathophysiology

Yogen Saunthararajah, Donald Lavelle Jul 17, 2025 pp. 268-270 10.1182/blood.2025029447

Weathering the HLH storm and redesigning clinical trials

Adi Zoref-Lorenz, Martin Ellis Jul 17, 2025 pp. 263-265 10.1182/blood.2025029715

Efficacy of a novel BCL-xL degrader, DT2216, in preclinical models of <i>JAK2</i>-mutated post-MPN AML

Zhe Wang, Anna Skwarska, Gowri Poigaialwar et al. Jul 17, 2025 pp. 341-355 10.1182/blood.2024027117

Abstract Acute myeloid leukemia (AML) that evolves from myeloproliferative neoplasm (MPN) is known as post-MPN AML. Current treatments do not significantly extend survival beyond 12...

Richter transformation recommendations

Birgitta Sander Jul 17, 2025 pp. 262-263 10.1182/blood.2025029450

Qualitative low VWF

Jul 17, 2025 pp. 398-398 10.1182/blood.2025030186

Novel, potent, and orally bioavailable LSD1 inhibitors induce fetal hemoglobin synthesis in a sickle cell disease mouse model

Yu Wang, Lei Yu, Kaiwen Deng et al. Jul 17, 2025 pp. 356-368 10.1182/blood.2024028006

Abstract Small molecules that inhibit LSD1 (lysine-specific demethylase 1, KDM1A) have been shown to induce abundant fetal hemoglobin (HbF) levels in red blood cells both in vitro an...

Ruxolitinib combined with dexamethasone for adult patients with newly diagnosed hemophagocytic lymphohistiocytosis in China

De Zhou, Xianbo Huang, Lixia Zhu et al. Jul 17, 2025 pp. 318-327 10.1182/blood.2024026139

Abstract Hemophagocytic lymphohistiocytosis (HLH) is a severe hyperinflammatory syndrome, and the overall survival (OS) of adult patients is poor. Ruxolitinib, a Janus kinase 1/2 (JA...

Unusual suspects: a surprise cast in making blood stem cells

Brandon Hadland Jul 17, 2025 pp. 265-266 10.1182/blood.2025029369

HNRNPC and m6A RNA methylation control oncogenic transcription and metabolism in T-cell leukemia

Jonas De Kesel, Igor Fijalkowski, Tim Pieters et al. Jul 17, 2025 pp. 275-290 10.1182/blood.2024026848

Abstract RNA homeostasis is dysregulated in cancer and affects disease progression and therapy resistance. N6-methyladenosine (m6A), the most abundant epitranscriptomic modification...

Proteostasis disruption in inherited bone marrow failure syndromes

Helena Yu, Robert A. J. Signer Jul 17, 2025 pp. 304-317 10.1182/blood.2024024956

Abstract Inherited bone marrow failure syndromes (IBMFS) are genetic disorders of impaired hematopoiesis that manifest in childhood with both cytopenias and extrahematologic findings...

Platelet NLRP6 protects against microvascular thrombosis in sepsis

Huimin Jiang, Shuang Chen, Xiang Gui et al. Jul 17, 2025 pp. 382-395 10.1182/blood.2025028739

Abstract Sepsis is characterized by a systemic inflammation and microvascular thrombosis induced by infection. The nucleotide-oligomerization domain–like receptor family pyrin domain...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page